Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

Compare

702 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MIRM Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Mirum

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MIRM Stock 12 Month Forecast

Average Price Target

$88.20

▲(29.50% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $88.20 with a high forecast of $95.00 and a low forecast of $77.00. The average price target represents a 29.50% change from the last price of $68.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"$39","96":"$96","53.25":"$53.3","67.5":"$67.5","81.75":"$81.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$88.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$77.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,53.25,67.5,81.75,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.65,74.36923076923077,76.08846153846154,77.8076923076923,79.52692307692308,81.24615384615385,82.96538461538462,84.68461538461538,86.40384615384616,88.12307692307692,89.8423076923077,91.56153846153846,93.28076923076924,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.65,73.84615384615385,75.0423076923077,76.23846153846155,77.43461538461538,78.63076923076923,79.82692307692308,81.02307692307693,82.21923076923078,83.41538461538462,84.61153846153846,85.8076923076923,87.00384615384615,{"y":88.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.65,72.9846153846154,73.31923076923077,73.65384615384616,73.98846153846154,74.32307692307693,74.65769230769232,74.99230769230769,75.32692307692308,75.66153846153847,75.99615384615385,76.33076923076923,76.66538461538461,{"y":77,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$95.00

Average Price Target$88.20

Lowest Price Target$77.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Thome

TD Cowen

$95

Buy

39.48%

Upside

Reiterated

11/05/25

Mirum Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating

Jonathan Wolleben

Citizens JMP

$81→$95

Buy

39.48%

Upside

Reiterated

11/05/25

Mirum Pharmaceuticals price target raised to $95 from $81 at Citizens JMPMirum Pharmaceuticals price target raised to $95 from $81 at Citizens JMP

Swayampakula Ramakanth

H.C. Wainwright

$80→$81

Buy

18.93%

Upside

Reiterated

11/05/25

Mirum Pharmaceuticals price target raised to $81 from $80 at H.C. WainwrightMirum Pharmaceuticals price target raised to $81 from $80 at H.C. Wainwright

Joshua Schimmer

Cantor Fitzgerald

$85→$95

Buy

39.48%

Upside

Reiterated

11/05/25

Mirum Pharmaceuticals price target raised to $95 from $85 at Cantor FitzgeraldMirum Pharmaceuticals price target raised to $95 from $85 at Cantor Fitzgerald

Gavin Clark-Gartner

Evercore ISI

$89

Buy

30.67%

Upside

Reiterated

11/05/25

Mirum Pharmaceuticals (MIRM) Receives a Buy from Evercore ISI3Q25: our stock scenarios on PSC & FXS

James Condulis

Stifel Nicolaus

$89→$92

Buy

35.08%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

Michael Ulz

Morgan Stanley

$81

Buy

18.93%

Upside

Reiterated

11/04/25

Mirum Pharmaceuticals (MIRM) Gets a Buy from Morgan StanleyAs progress continues towards multiple catalysts beginning next year; We reiterate our Overweight rating.

Mani Foroohar

Leerink Partners

$66→$88

Buy

29.20%

Upside

Reiterated

10/15/25

Jessica Fye

J.P. Morgan

$53→$77

Buy

13.05%

Upside

Reiterated

09/12/25

Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorganMirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan

David Lebowitz

Citi

$89

Buy

30.67%

Upside

Reiterated

08/18/25

Analysts Are Bullish on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), Century Therapeutics (IPSC)We hosted Mirum co-founder and CEO a virtual fireside chat (replay HERE). We discussed the company’s rare disease franchise specializing in developing ileal bile acid transporter (IBATs) to target cholestatic disorders, which are caused by bile acid buildup due to reduced/blocked flow from the liver. IBATs can significantly decrease the debilitating itching (aka pruritus) symptoms experienced by patients. Mirum’s primary asset in Livmarli is approved for two cholestatic genetic diseases and has been outperforming sales expectations over the past few quarters, bringing in $88.2M most recently in 2Q25. Mgt believes a potential label expansion for Livmarli to patients with other ultra-rare choleastic diseases could propel the drug to blockbuster status.

Ryan Deschner

Raymond James

$77→$82

Buy

20.39%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond JamesMirum Pharmaceuticals price target raised to $82 from $77 at Raymond James

Brian Skorney

Robert W. Baird

$55→$72

Buy

5.71%

Upside

Reiterated

08/07/25

Robert W. Baird Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)

Ed Arce

Westpark Capital

$66→$72

Buy

5.71%

Upside

Reiterated

02/27/25

Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Thome

TD Cowen

$95

Buy

39.48%

Upside

Reiterated

11/05/25

Mirum Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating

Jonathan Wolleben

Citizens JMP

$81→$95

Buy

39.48%

Upside

Reiterated

11/05/25

Mirum Pharmaceuticals price target raised to $95 from $81 at Citizens JMPMirum Pharmaceuticals price target raised to $95 from $81 at Citizens JMP

Swayampakula Ramakanth

H.C. Wainwright

$80→$81

Buy

18.93%

Upside

Reiterated

11/05/25

Mirum Pharmaceuticals price target raised to $81 from $80 at H.C. WainwrightMirum Pharmaceuticals price target raised to $81 from $80 at H.C. Wainwright

Joshua Schimmer

Cantor Fitzgerald

$85→$95

Buy

39.48%

Upside

Reiterated

11/05/25

Mirum Pharmaceuticals price target raised to $95 from $85 at Cantor FitzgeraldMirum Pharmaceuticals price target raised to $95 from $85 at Cantor Fitzgerald

Gavin Clark-Gartner

Evercore ISI

$89

Buy

30.67%

Upside

Reiterated

11/05/25

Mirum Pharmaceuticals (MIRM) Receives a Buy from Evercore ISI3Q25: our stock scenarios on PSC & FXS

James Condulis

Stifel Nicolaus

$89→$92

Buy

35.08%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

Michael Ulz

Morgan Stanley

$81

Buy

18.93%

Upside

Reiterated

11/04/25

Mirum Pharmaceuticals (MIRM) Gets a Buy from Morgan StanleyAs progress continues towards multiple catalysts beginning next year; We reiterate our Overweight rating.

Mani Foroohar

Leerink Partners

$66→$88

Buy

29.20%

Upside

Reiterated

10/15/25

Jessica Fye

J.P. Morgan

$53→$77

Buy

13.05%

Upside

Reiterated

09/12/25

Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorganMirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan

David Lebowitz

Citi

$89

Buy

30.67%

Upside

Reiterated

08/18/25

Ryan Deschner

Raymond James

$77→$82

Buy

20.39%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond JamesMirum Pharmaceuticals price target raised to $82 from $77 at Raymond James

Brian Skorney

Robert W. Baird

$55→$72

Buy

5.71%

Upside

Reiterated

08/07/25

Robert W. Baird Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)

Ed Arce

Westpark Capital

$66→$72

Buy

5.71%

Upside

Reiterated

02/27/25

Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

1 Month

xxx

Success Rate

19/32 ratings generated profit

Average Return

+2.62%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.38% of your transactions generating a profit, with an average return of +2.62% per trade.

3 Months

xxx

Success Rate

21/32 ratings generated profit

Average Return

+10.59%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.63% of your transactions generating a profit, with an average return of +10.59% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

17/18 ratings generated profit

Average Return

+46.78%

reiterated a buy rating 5 days ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +46.78% per trade.

2 Years

xxx

Success Rate

18/18 ratings generated profit

Average Return

+107.73%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +107.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MIRM Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MIRM has received 13 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the past 3 months is 88.20.

Each month's total comprises the sum of three months' worth of ratings.

MIRM Financial Forecast

MIRM Earnings Forecast

Next quarter’s earnings estimate for MIRM is -$0.05 with a range of -$0.18 to $0.08. The previous quarter’s EPS was $0.05. MIRM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year MIRM has Preformed in-line its overall industry.

MIRM Sales Forecast

Next quarter’s sales forecast for MIRM is $136.75M with a range of $131.00M to $145.00M. The previous quarter’s sales results were $133.01M. MIRM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year MIRM has Preformed in-line its overall industry.

MIRM Stock Forecast FAQ

What is MIRM’s average 12-month price target, according to analysts?

Based on analyst ratings, Mirum Pharmaceuticals Inc’s 12-month average price target is 88.20.

What is MIRM’s upside potential, based on the analysts’ average price target?

Mirum Pharmaceuticals Inc has 29.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MIRM a Buy, Sell or Hold?

Mirum Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mirum Pharmaceuticals Inc’s price target?

The average price target for Mirum Pharmaceuticals Inc is 88.20. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $95.00 ,the lowest forecast is $77.00. The average price target represents 29.50% Increase from the current price of $68.11.

What do analysts say about Mirum Pharmaceuticals Inc?

Mirum Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of MIRM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

MIRM Analyst Ratings

MIRM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mirum Pharmaceuticals

MIRM Analyst Recommendation Trends

MIRM Financial Forecast

MIRM Earnings Forecast

MIRM Sales Forecast

MIRM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts